Clinical Trial Update: A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele [Phase 2]

View source ↗

Summary

Phase 2 study assessing ELX-02 in cystic fibrosis patients with the G542X allele has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ELX-02 (ELX-02)

Snippet

Sponsor: Eloxx Pharmaceuticals, Inc. | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED